PMID- 29318902
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20220321
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 14
IP  - 2
DP  - 2018 Feb
TI  - Interferon beta-1a and beta-1b for patients with multiple sclerosis: updates to current 
      knowledge.
PG  - 137-153
LID - 10.1080/1744666X.2018.1426462 [doi]
AB  - Although multiple sclerosis (MS) remains incurable, interferon beta (IFNbeta) has 
      been at the forefront of treatment for many years. Different formulations of IFNbeta 
      allow for different levels of exposure: low-dose/frequency with some agents, and 
      high-dose/frequency with others. Areas covered: This review article discusses 
      existing and emerging efficacy and safety data for IFNbeta in MS. Clinical evidence 
      of IFNbeta efficacy has been generated and accumulated over many decades. During 
      this time, key clinical trials have demonstrated the benefits of high-dose and/or 
      high-frequency dosing of IFNbeta-1a or beta-1b, compared with lower levels of exposure, 
      on outcome measures such as relapse rates, disability progression, disease 
      progression and magnetic resonance imaging lesion outcomes. IFNbeta therapy is well 
      tolerated and has one of the best characterized safety profiles of all first line 
      therapies. The overall severity of adverse events (AEs) does not appear to be 
      affected by different IFNbeta exposures. Typical AEs that patients may experience 
      with IFNbeta are mild, reversible and manageable. Expert commentary: IFNbeta is one of 
      the best characterized treatments for MS, with a large body of clinical and 
      real-world evidence supporting the risk-benefit profile. High-dose/frequency 
      regimens may provide better long-term outcomes.
FAU - Zettl, Uwe Klaus
AU  - Zettl UK
AD  - a Department of Neurology, Neuroimmunology Section , University of Rostock , 
      Rostock , Germany.
FAU - Hecker, Michael
AU  - Hecker M
AD  - a Department of Neurology, Neuroimmunology Section , University of Rostock , 
      Rostock , Germany.
FAU - Aktas, Orhan
AU  - Aktas O
AD  - b Department of Neurology, Medical Faculty , Heinrich Heine University , 
      Dusseldorf , Germany.
FAU - Wagner, Torsten
AU  - Wagner T
AD  - c Department of Medical Affairs , Merck KGaA , Darmstadt , Germany.
FAU - Rommer, Paulus S
AU  - Rommer PS
AD  - d Department of Neurology , Medical University of Vienna , Vienna , Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180123
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Drug Dosage Calculations
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Expert Testimony
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Interferon-beta/*therapeutic use
MH  - Multiple Sclerosis/immunology/*therapy
MH  - Risk Assessment
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Multiple sclerosis
OT  - clinically isolated syndrome
OT  - interferon beta
OT  - relapsing-remitting multiple sclerosis
OT  - secondary progressive multiple sclerosis
EDAT- 2018/01/11 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/01/11 06:00
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/01/11 06:00 [entrez]
AID - 10.1080/1744666X.2018.1426462 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2018 Feb;14(2):137-153. doi: 
      10.1080/1744666X.2018.1426462. Epub 2018 Jan 23.